Pacira BioSciences Inc (PCRX)
26.24
+0.14
(+0.54%)
USD |
NASDAQ |
Apr 19, 16:00
26.24
0.00 (0.00%)
After-Hours: 20:00
Pacira BioSciences Enterprise Value: 1.458B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.458B |
| April 17, 2024 | 1.489B |
| April 16, 2024 | 1.493B |
| April 15, 2024 | 1.478B |
| April 12, 2024 | 1.491B |
| April 11, 2024 | 1.516B |
| April 10, 2024 | 1.538B |
| April 09, 2024 | 1.570B |
| April 08, 2024 | 1.568B |
| April 05, 2024 | 1.553B |
| April 04, 2024 | 1.564B |
| April 03, 2024 | 1.593B |
| April 02, 2024 | 1.570B |
| April 01, 2024 | 1.599B |
| March 28, 2024 | 1.603B |
| March 27, 2024 | 1.594B |
| March 26, 2024 | 1.570B |
| March 25, 2024 | 1.603B |
| March 22, 2024 | 1.577B |
| March 21, 2024 | 1.606B |
| March 20, 2024 | 1.640B |
| March 19, 2024 | 1.614B |
| March 18, 2024 | 1.606B |
| March 15, 2024 | 1.611B |
| March 14, 2024 | 1.604B |
| Date | Value |
|---|---|
| March 13, 2024 | 1.652B |
| March 12, 2024 | 1.665B |
| March 11, 2024 | 1.686B |
| March 08, 2024 | 1.704B |
| March 07, 2024 | 1.669B |
| March 06, 2024 | 1.644B |
| March 05, 2024 | 1.613B |
| March 04, 2024 | 1.602B |
| March 01, 2024 | 1.586B |
| February 29, 2024 | 1.626B |
| February 28, 2024 | 1.635B |
| February 27, 2024 | 1.632B |
| February 26, 2024 | 1.627B |
| February 23, 2024 | 1.640B |
| February 22, 2024 | 1.637B |
| February 21, 2024 | 1.624B |
| February 20, 2024 | 1.632B |
| February 16, 2024 | 1.596B |
| February 15, 2024 | 1.622B |
| February 14, 2024 | 1.603B |
| February 13, 2024 | 1.602B |
| February 12, 2024 | 1.639B |
| February 09, 2024 | 1.582B |
| February 08, 2024 | 1.531B |
| February 07, 2024 | 1.568B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.208B
Minimum
Mar 23 2020
4.150B
Maximum
Apr 08 2022
2.309B
Average
2.258B
Median
Enterprise Value Benchmarks
| Dynavax Technologies Corp | 962.87M |
| Arbutus Biopharma Corp | 367.68M |
| Chimerix Inc | -100.59M |
| Karyopharm Therapeutics Inc | 126.19M |
| FibroGen Inc | -7.110M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 24.87M |
| Revenue (Quarterly) | 181.24M |
| Total Expenses (Quarterly) | 147.28M |
| EPS Diluted (Quarterly) | 0.52 |
| Gross Profit Margin (Quarterly) | 73.69% |
| Profit Margin (Quarterly) | 13.72% |
| Earnings Yield | 3.16% |
| Operating Earnings Yield | 6.08% |
| Normalized Earnings Yield | 4.310 |